Top

Published in:

01-03-2021 | Lymphoma | Original Article

Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma

Authors: Qiqi Zhu, Xueqin Deng, Wenqing Yao, Zihang Chen, Yunxia Ye, Limin Gao, Wenyan Zhang, Weiping Liu, Sha Zhao

Published in: Annals of Hematology | Issue 3/2021

Abstract

Tumour-infiltrating lymphocytes (TILs) account for a large proportion of tumour microenvironment (TME) in angioimmunoblastic T cell lymphoma (AITL), and at present the significance of TIL in TME of AITL remains unclear. Overall, 50 de novo AITL patients undergoing lymph node flow cytometry from 2014 to 2019 were retrospectively analysed to assess the relationship between TILs and AITL prognosis. We found that high TIL-Bs (≥ 42.4%, p = 0.004) and high CD4:CD8 (≥ 0.85, p = 0.024) were independent favourable prognostic factors for de novo AITL in univariate or multivariate analyses. New TIL-related risk stratification was established based on TIL-Bs and CD4:CD8 factors. Patients in the low-risk group (TIL-Bs ≥ 42.4% and CD4:CD8 ≥ 0.85) had significantly better overall survival than the high-risk (TIL-Bs < 42.4% and CD4:CD8 < 0.85) (p < 0.001) or intermediate-risk group (TIL-Bs ≥ 42.4% and CD4:CD8 < 0.85 or TIL-Bs < 42.4% and CD4:CD8 ≥ 0.85) (p = 0.011). To our knowledge, our cohort is the largest one focusing on the TILs in de novo cases of AITL by analysing lymph node samples using flow cytometry, which is the first time to comprehensively consider humoral immunity and cellular immunity influence on AITL. Our new risk stratification was valuable and useful in evaluating prognosis of AITL and guiding immunotherapy strategies.

Available only for authorised users

Chiba S, Sakata-Yanagimoto M (2020) Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia 34(10):2592–2606PubMedCrossRefPubMedCentral

Lemonnier F, Mak TW (2017) Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol 242(4):387–390PubMedCrossRef

Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111(9):4463–4470PubMedPubMedCentralCrossRef

Lunning MA, Vose JM (2017) Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 129(9):1095–1102PubMedCrossRef

De Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148(5):673–689PubMedCrossRef

Merchant SH, Amin MB, Viswanatha DS (2006) Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol 126(1):29–38PubMedCrossRef

De Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Briere J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952–4963PubMedCrossRef

Bruneau J, Canioni D, Renand A, Marafioti T, Paterson JC, Martin-Garcia N, Gaulard P, Delfau MH, Hermine O, Macintyre E (2010) Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol 177(2):570–574PubMedPubMedCentralCrossRef

Chen Z, Deng X, Ye Y, Gao L, Zhang W, Liu W, Zhao S (2019) Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry. Ann Hematol 98(2):391–399PubMedCrossRef

10.

Hui L, Chen Y (2015) Tumor microenvironment: sanctuary of the devil. Cancer Lett 368(1):7–13CrossRefPubMed

11.

Wu T, Dai Y(2017) Tumor microenvironment and therapeutic response. Cancer Lett 38761-68

12.

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M (2017) Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials. Cancer Treat Rev 57:8–15PubMedCrossRef

13.

Li J, Wang J, Chen R, Bai Y, Lu X (2017) The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 8(9):15621–15631PubMedPubMedCentralCrossRef

14.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL (2017) B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Cli Cancer Res: Off J Am Assoc Cancer Res 23(17):5202–5209CrossRef

15.

Miksch RC, Schoenberg MB, Weniger M, Bosch F, Ormanns S, Mayer B, Werner J, Bazhin AV, D'Haese JG (2019) Prognostic impact of tumor-infiltrating lymphocytes and neutrophils on survival of patients with upfront resection of pancreatic cancer. Cancers (Basel) 11(1):39CrossRef

16.

Berntsson J, Nodin B, Eberhard J, Micke P, Jirstrom K (2016) Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 139(5):1129–1139PubMedCrossRef

17.

Alikhan M, Song JY, Sohani AR, Moroch J, Plonquet A, Duffield AS, Borowitz MJ, Jiang L, Bueso-Ramos C, Inamdar K, Menon MP, Gurbuxani S, Chan E, Smith SM, Nicolae A, Jaffe ES, Gaulard P, Venkataraman G (2016) Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(−/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Modern Pathol: Off J United States Can Acad Pathol 29(10):1173–1182CrossRef

18.

Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, Nebe T, Florcken A, van Lessen A, Anagnostopoulos I, Dorken B, Ludwig WD, Pezzutto A, Westermann J (2014) Peripheral blood sCD3(−) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 32(1):16–21PubMedCrossRef

19.

Pizzolo G, Vinante F, Agostini C, Zambello R, Trentin L, Masciarelli M, Chilosi M, Benedetti F, Dazzi F, Todeschini G et al (1987) Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer 60(10):2412–2418PubMedCrossRef

20.

Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr (2014) Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol (Clifton, NJ) 1102:287–324CrossRef

21.

Yu PC, Long D, Liao CC, Zhang S (2018) Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer. Medicine 97(27):e11387PubMedPubMedCentralCrossRef

22.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haioun C, Gaulard P, Mahevas M (2019) Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol 103(1):35–42PubMedCrossRef

23.

Choi CH, Park YH, Lim JH, Choi SJ, Kim L, Park IS, Han JY, Kim JM, Chu YC (2016) Prognostic implication of semi-quantitative Immunohistochemical assessment of CD20 expression in diffuse large B-cell lymphoma. J Pathol Transl Med 50(2):96–103PubMedPubMedCentralCrossRef

24.

Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF (2007) Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A 104(52):20878–20883PubMedPubMedCentralCrossRef

25.

Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol (Baltimore, Md : 1950) 176(6):3498–3506CrossRef

26.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Cli Cancer Res : Off J Am Assoc Cancer Res 18(12):3281–3292CrossRef

27.

Hladikova K, Koucky V, Boucek J, Laco J, Grega M, Hodek M, Zabrodsky M, Vosmik M, Rozkosova K, Vosmikova H, Celakovsky P, Chrobok V, Ryska A, Spisek R, Fialova A (2019) Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J Immunother Cancer 7(1):261PubMedPubMedCentralCrossRef

28.

Xu X, Tan Y, Qian Y, Xue W, Wang Y, Du J, Jin L, Ding W (2019) Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: a meta-analysis. Medicine 98(2):e13923PubMedPubMedCentralCrossRef

29.

Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, Kalogeras KT, Kellokumpu-Lehtinen PL, Fountzilas G, Wirtz RM, Joensuu H (2018) Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer res: BCR 20(1):15PubMedCrossRefPubMedCentral

30.

Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE (2009) Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am 49(5):651–681CrossRef

31.

Clifford GM, Franceschi S (2009) Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol (London, England) 5(5):669–678CrossRef

32.

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360(18):1815–1826PubMedPubMedCentralCrossRef

33.

Huang H, Hao S, Li F, Ye Z, Yang J, Xiang J (2007) CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 120(2):148–159PubMedPubMedCentralCrossRef

34.

Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA (2008) IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A 105(13):5201–5206PubMedPubMedCentralCrossRef

35.

Crotty S(2011) Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29621–663

36.

Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR, Al-Saleem T (2017) Low level of blood CD4(+) T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma. Clin Lymphoma, Myeloma Leuk 17(2):83–88CrossRef

37.

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123(7):2873–2892PubMedPubMedCentralCrossRef

38.

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641–645PubMedPubMedCentralCrossRef

39.

Javeed I, George W, Chao W, Andreas R, Gascoyne RD, Weisenburger DD, Greiner TC, Lynette S, Shuangping G, Wilcox RA (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915CrossRef

40.

Li B, Cui Y, Nambiar DK, Sunwoo JB, Li R (2019) The immune subtypes and landscape of squamous cell carcinoma. Cli Cancer Res: Off J Am Assoc Cancer Res 25(12):3528–3537

41.

Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M (2019) Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res 7(6):886–895PubMedPubMedCentralCrossRef

42.

Igarashi T, Takahashi H, Tobe T, Suzuki H, Mizoguchi K, Nakatsu HO, Ito H (2002) Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma. Urol Int 69(1):51–56PubMedCrossRef

43.

Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61(13):5132–5136PubMed

44.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB, Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S (2018) Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med 24(7):986–993PubMedCrossRef

45.

Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol Off J Am Soc Clin Oncol 31(2):240–246CrossRef

46.

Zain JM (2019) Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am J Hematol 94(8):929–946PubMedCrossRef

47.

Moskowitz AJ (2019) Practical treatment approach for Angioimmunoblastic T-cell lymphoma. J Oncol Pract 15(3):137–143PubMedPubMedCentralCrossRef

Title: Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma
Authors: Qiqi Zhu
Xueqin Deng
Wenqing Yao
Zihang Chen
Yunxia Ye
Limin Gao
Wenyan Zhang
Weiping Liu
Sha Zhao
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keyword: Lymphoma
Published in: Annals of Hematology / Issue 3/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04389-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Hematologic changes predict clinical outcome in recovered patients with COVID-19

Effects of three months of treatment with vitamin E and N-acetyl cysteine on the oxidative balance in patients with transfusion-dependent β-thalassemia

Utilization of radiation therapy in multiple myeloma: trends and changes in practice

Risk factors and predictors of treatment responses and complications in immune thrombocytopenia

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page